Oral safety testing of OLX-07010 in dogs to support Alzheimer’s disease trials
Official title: A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period
Funded at Oligomerix, INC · NIH-11530730 · Data updated 2026-11-12
A short-term dog safety study is being done to help move OLX-07010 toward studies in people with Alzheimer’s disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oligomerix, INC NIH-funded |
| Lab location | 1 site (Bronx, UNITED STATES) |
| Project start | August 20, 2025 |
| Project end | February 29, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,499,525 |
| NIH project number | 4R44AG091987-02 |
| Project ID | NIH-11530730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Alzheimer’s disease or related dementias are the potential beneficiaries of future trials using OLX-07010, pending successful safety studies.
✕Less likely to help
Healthy individuals or those not eligible for AD-related trials would not directly benefit from this specific canine toxicity study.
What this research studies
This project tests the safety of OLX-07010 when given by mouth to beagle dogs for 13 weeks, followed by 4 weeks of recovery. The goal is to identify potential risks before longer human trials in patients with Alzheimer’s disease or related dementias. Results will inform a larger 39-week toxicology study required by the FDA and help determine safe dosing for future phase 1b studies in patients. The sponsor emphasizes that the work is part of developing a treatment that targets tau protein to slow or prevent disease progression.
Why it matters
Potential benefit: If successful, the study could support safer dosing and faster progression toward clinical testing for OLX-07010 in Alzheimer’s patients.
How similar studies have gone: Similar GLP toxicology studies are a standard step in advancing a tau-targeting Alzheimer’s therapy and can enable subsequent human trials.
Where this research is happening
-
Oligomerix, INC
Bronx, United States Active
Researchers
- Principal investigator: Moe, James G. — Oligomerix, INC
- Study coordinator: Moe, James G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.